Travere Therapeutics Inc. (TVTX)
| Bid | 20.42 |
| Market Cap | 1.85B |
| Revenue (ttm) | 233.18M |
| Net Income (ttm) | -321.55M |
| EPS (ttm) | -4.07 |
| PE Ratio (ttm) | -5.11 |
| Forward PE | 24.76 |
| Analyst | Buy |
| Ask | 21.9 |
| Volume | 1,489,898 |
| Avg. Volume (20D) | 1,828,809 |
| Open | 20.73 |
| Previous Close | 20.81 |
| Day's Range | 20.31 - 21.00 |
| 52-Week Range | 5.79 - 25.29 |
| Beta | 0.84 |
About TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzy...
Analyst Forecast
According to 14 analyst ratings, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 53.77% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
4 hours ago · businesswire.com
Travere Therapeutics Reports First Quarter 2025 Financial ResultsSAN DIEGO--(BUSINESS WIRE)-- #1Q25earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update. “As the only fully approv...
2 months ago · seekingalpha.com
Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call TranscriptTravere Therapeutics, Inc. (NASDAQ:TVTX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and...
